Health

FDA grants Pfizer vaccine green light for use in kids aged 12 to 15

Pfizer’s COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration on Monday for use in children aged 12 to 15.

“Today’s action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic,” Acting FDA Commissioner Janet Woodcock, said in a statement. “Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.”

FDA MEETING ON COVID-19 VACCINES IN KIDS ON JUNE 10

In results from trials conducted among the younger group the vaccine showed 100% efficacy and robust antibody response, Pfizer previously said. Side effects were similar to those experienced by adults.

BioNTech SE and Pfizer previously said they hoped the vaccine would be available to children in this age group before the start of the school year next fall.

The companies recently announced they are seeking full regulatory approval of their vaccine.

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

According to CDC data, there were about 1.5 million COVID-19 cases reported in individuals aged 11 to 17 as of the end of April, though the infections in this age group have tended to be milder.

As previously reported by Fox News, the FDA is expected to hold a meeting next month where it will discuss vaccines in children.

Pfizer received authorization for use in individuals aged 16 and over late last year.

So far nearly 140 million doses of the Pfizer vaccine have been administered in the U.S., according to the CDC.

WHO elevates Indian coronavirus strain to ‘variant of concern’

A top official at the World Health Organization on Monday announced the agency is elevating a coronavirus variant first identified in India from a ‘variant to interest,’ to a ‘variant to concern,’ citing early studies suggesting increased transmissibility.

Dr. Maria Van Kerkhove, WHO’s COVID-19 technical lead, said during a press conference that the B.1.617 variant appeared to spread more readily in preliminary studies released ahead of peer review. But there are still many unknowns around the impact on diagnostics, therapeutics, and vaccines, she noted.

Kerkhove said the agency needs much more information around the variant and its three sublineages, such as neutralization and any increased severity, through targeted sequencing. This information could help scientists understand the degree to which the variant is circulating in India and other countries.

ABOUT 20 CASES OF INDIAN CORONAVIRUS VARIANT DETECTED IN FRANCE

Additional information is expected to be released Tuesday, she said.

Kerkhove urged the already-established public health measures like distancing, hand hygiene, mask use, avoiding crowded spaces and improving ventilation to prevent against infection from all strains of the virus.

While the U.S. Centers for Disease Control and Prevention currently lists the Indian variant and its sublineages as a “variant of interest,” U.K. health officials have already moved to classify the Indian virus variant as a “variant of concern” in the country following an uptick in cases and “evidence of community transmission.”

GET THE FOX NEWS APP

Public Health England cited evidence suggesting the variant is “at least as transmissible” as the U.K. B.1.1.7 variant, which is believed to spread 50% more easily than the ancestral strain.

“There is currently insufficient evidence to indicate that any of the variants recently detected in India cause more severe disease or render the vaccines currently deployed any less effective,” PHE wrote in a statement posted Friday. “PHE is carrying out laboratory testing, in collaboration with academic and international partners to better understand the impact of the mutations on the behaviour of the virus.”

Coronavirus can spread more than 6 feet in certain conditions, CDC warns

The novel coronavirus is capable of spreading more than six feet through the air in certain instances, according to the Centers for Disease Control and Prevention (CDC).

In an update posted Friday, the CDC on its page entitled “Scientific Brief: SARS-CoV-2 Transmission” warned of “repeatedly documented” instances of the novel virus spreading through the air to people more than six feet away.

“With increasing distance from the source, the role of inhalation likewise increases,” the CDC said. “Although infections through inhalation at distances greater than six feet from an infectious source are less likely than at closer distances, the phenomenon has been repeatedly documented under certain preventable circumstances.”

“These transmission events have involved the presence of an infectious person exhaling virus indoors for an extended time (more than 15 minutes and in some cases hours) leading to virus concentrations in the air space sufficient to transmit infections to people more than 6 feet away, and in some cases to people who have passed through that space soon after the infectious person left,” the federal health agency continued.

ABOUT 20 CASES OF INDIAN CORONAVIRUS VARIANT DETECTED IN FRANCE

The CDC proceeded to note several circumstances where this occurrence is more likely, such as in enclosed spaces with “inadequate ventilation or air handling within which the concentration of exhaled respiratory fluids, especially very fine droplets, and aerosol particles, can build up in the air space.”

Other instances include “increased exhalation of respiratory fluids” from the infected person, such as if they are exercising, shouting, or singing, per the CDC.

“Prolonged exposure to these conditions, typically more than 15 minutes,” was also cited as a factor that increases the risk of SARS-CoV-2 infection under such circumstances.

COVID-19 VACCINE DESERTS: SOME COUNTRIES HAVE NO SHOTS AT ALL

The update comes after the CDC in October revised its coronavirus guidance to acknowledge the potential for infection through virus-laden particles lingering in the air in enclosed areas with poor ventilation.

“Although how we understand transmission occurs has shifted, the ways to prevent infection with this virus have not,” the CDC said in its update posted Friday. “All prevention measures that CDC recommends remain effective for these forms of transmission,” such as wearing a face mask in crowded spaces, frequently washing your hands, and receiving the COVID-19 vaccine, per the federal health agency.

Fox News’ Kayla Rivas contributed to this report.

FDA meeting on COVID-19 vaccines in kids on June 10

The Food and Drug Administration (FDA) announced a June 10 advisory committee meeting to discuss COVID-19 vaccines in pediatric populations amid speculation that the agency would decide on Pfizer-BioNTech’s request to expand emergency use authorization (EUA) for its shot to teens ages 12-15 within the coming days.

The memo was sent just two days before the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is set to meet, although as of Monday there was no draft agenda for the meeting available on the agency’s website.

It was widely believed that the FDA would issue a decision on Pfizer-BioNTech’s request early this week, with Dr. Anthony Fauci speculating that the agency would take “several days” to respond to the companies’ request. It was not clear if the announcement of the June 10 meeting would impact the agency’s plans regarding a decision.

CDC COULD SOON EASE INDOOR MASK GUIDANCE, FAUCI SAYS

“Vaccines continue to be an important public health measure in fighting the COVID-19 pandemic,” said Dr. Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “To date, the FDA has authorized three COVID-19 vaccines for emergency use that have met our rigorous standards for quality, safety and effectiveness — two are authorized for individuals 18 and older, and one is authorized for individuals 16 and older.

“We recognize that the next critical step is having vaccines available for use throughout the pediatric population,” Marks continued. “As with the initial COVID-19 vaccine authorizations, we want to ensure that the public has a clear understanding of our expectations for the data and information needed to support requests for emergency use authorization and biologics license applications for vaccines intended to prevent COVID-19 in this pediatric age range.”

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

Fox News has requested additional comments from the FDA and CDC.

CDC could ease coronavirus indoor mask guidance: Fauci, Gottlieb

With over one-third of U.S. adults fully vaccinated against coronavirus and the seven-day average for new infections substantially down from winter-time peaks, Dr. Anthony Fauci and former FDA commissioner Dr. Scott Gottlieb suggest it’s time to ease indoor mask guidance.

While the CDC updated its mask guidance last month, advising fully vaccinated populations can go without masks outdoors except in crowded settings, the agency still says fully vaccinated people should wear masks indoors around unvaccinated people from multiple households, and in indoor public settings like movie theaters, malls, museums and restaurants. The agency also recently published a brief indicating small virus droplets can travel more than six feet under certain conditions, posing a risk for infection.

ABOUT 20 CASES OF INDIAN CORONAVIRUS VARIANT DETECTED IN FRANCE

However, Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical adviser to President Biden, said Sunday on ABC’s “This Week” he believes Gottlieb is correct in saying the country could see a shift in indoor mask guidance, and the guidance should be more “liberal” as the vaccination drive continues.

“No I think so, I think you’re going to probably see that as we go along and as more people get vaccinated,” Fauci told ABC’s George Stephanopoulos. “The CDC will be, almost in real-time George, updating their recommendations and their guidelines. We do need to start being more liberal as we get more people vaccinated.”

“As you get more people vaccinated, the number of cases per day will absolutely go down. We’re averaging about 43,000 a day, we’ve got to get it much, much lower than that. When that gets lower, the risk of any infection indoor or outdoor diminishes dramatically,” he said.

The CDC did not respond to Fox News’ request for comment Monday morning.

In a separate interview with NBC’s “Meet the Press,” Fauci suggested people could opt to don masks seasonally to tamp down on the flu.

COVID-19 VACCINE DESERTS: SOME COUNTRIES HAVE NO SHOTS AT ALL

“It is conceivable that as we go on a year or two or more from now, that during certain seasonal periods when you have respiratory borne viruses like the flu, people might actually elect to wear masks to diminish the likelihood that you’ll spread these respiratory borne diseases.”

Jeffrey Zients, the White House COVID-19 Response Coordinator, during an interview Sunday on CNN’s “State of the Union,” was more conservative in his response. The outlet’s Jake Tapper noted growing frustrations among “journalists and some health experts” that “overly cautious” mask guidance could undermine confidence in “a light at the end of the tunnel.”

“I think everyone is tired, and wearing a mask can be a pain but we’re getting there and the light at the end of the tunnel is brighter and brighter,” Zients said. “Let’s keep up our guard, let’s follow the CDC guidance. And the CDC guidance across time will allow vaccinated people more and more privileges to take off that mask.”

GET THE FOX NEWS APP

Meanwhile, Gottlieb told CBS’ “Face the Nation” Sunday that vaccinations and immunity from prior COVID-19 infection will “substantially” drive down risks of COVID-19.

“We’re at the point right now where we can start lifting these ordinances and allowing people to resume normal activity, certainly outdoors we shouldn’t be putting limits on gatherings anymore, we should be encouraging people to go outside,” Gottlieb said. “In the states where prevalence is low, vaccination rates are high and we have good testing in place and we’re identifying infections, I think we can start lifting these restrictions indoors as well on a broad basis.”

Gottlieb told CNBC’s Shepard Smith last week that a lifting of CDC indoor mask mandates now amid improved case counts would help “preserve the credibility of public health officials” if the provisions need to be re-introduced during winter-time outbreaks.

Mother’s Day 2022: Fauci predicts country will be ‘as close to back to normal as we can’ by next year

Dr. Anthony Fauci predicted Sunday that America will be “as close to back to normal as we can” by next Mother’s Day if certain conditions are met.

Fauci, director of the National Institutes of Allergy and Infectious Diseases and the White House’s chief medical adviser, made the prediction during ABC’s “This Week” with George Stephanopoulos, who had asked him to “give everyone a sense of what the country is going to look like next Mother’s Day.”

“I hope that next Mother’s Day, we’re going to see a dramatic difference than what we’re seeing right now. I believe that we will be about as close to back to normal as we can. And there’s some conditions to that, George,” Fauci said during the segment. “We’ve got to make sure that we get the overwhelming proportion of the population vaccinated.”

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks during a press briefing at the White House, Tuesday, April 13, 2021, in Washington. (AP Photo/Patrick Semansky)

When the majority of Americans are vaccinated, he said, COVID-19 “doesn’t really have any place to go.”

FAUCI SAYS US IS IN ‘BOTTOM OF THE SIXTH’ IN COVID-19 TIMELINE

“There aren’t a lot of vulnerable people around. And where there are not a lot of vulnerable people around, you’re not going to see a surge. You’re not going to see the kinds of numbers we see now,” he said. “That being the case, I think we can approach what we use to remember as normal before all of this tragedy happened.”

Fauci was also asked during the segment what more he believes could be done to address India’s startling surge in coronavirus cases.

Infections have swelled in India since February in a disastrous turn blamed on more contagious variants as well as government decisions to allow massive crowds to gather for religious festivals and political rallies. On Friday India reported a new daily record of 414,188 confirmed cases and 3,915 additional deaths. The official daily death count has stayed over 3,000 for the past 10 days.

100M FULLY VACCINATED AGAINST CORONAVIRUS, WHITE HOUSE SAYS

Fauci said he had several suggestions and has spoken with Indian officials on the matter.

“They really got to get hospital beds and do really what the Chinese did way back a year or so ago, where you essentially build up with – the equivalent of field hospitals. You’ve got to get that,” Fauci said. “You can’t have people out in the street not having a hospital bed.”

He also called the lack of available oxygen for patients “really critical.”

“But the end game of this all, George, is going to be to get people vaccinated,” Fauci said. “India is the largest vaccine producing country in the world, they’ve got to get their resources not only from within but also from without and that’s the reason why other countries need to chip in to be able to get either supplies to the Indians to make their own vaccines or to get vaccines donated.”

Another way to increase vaccine production numbers is to have companies that are already capable of making vaccines “really scale up” in production for the nation.

Fauci also said he has advised Indian authorities to “shut down” the country “to break the chain of transmission.”

Over the past month, nearly a dozen of India’s 28 federal states have announced some restrictions, but they fall short of a nationwide lockdown imposed last year that experts credit with helping to contain the virus for a time.

Many medical experts, opposition leaders and even supreme court judges have called for national restrictions, arguing that a patchwork of state rules is insufficient to quell the rise in infections.

Meanwhile, on NBC’s “Meet the Press” on Sunday, Fauci was asked about a University of Washington analysis that found that over 900,000 Americans – more than double what had been counted – have died from COVID-19.

“We’ve been saying, and the CDC has been saying all along, that it is very likely that we’re undercounting,” he told NBC’s Chuck Todd.

CLICK HERE TO GET THE FOX NEWS APP

“I think there’s no doubt, Chuck, that we are and have been undercounting,” Fauci continued. “What that tells us is something that we’ve known … we’re living through a historic pandemic, the likes of which we haven’t seen in over 100 years.”

The Associated Press contributed to this report.

Ducking their shots: Walter Reed whistleblower wants military to step up

Charles Eggleston served more than 16 years in the Army – and more than 3 years as a patient at Walter Reed after being hit by a roadside bomb on his 3rd tour in Iraq.

“I’ve had all kinds of vaccines,” said Eggleston, who served in Baghdad with 107th Cavalry in 2003, 2004 and 2005. “I definitely wasn’t trying to die from sheer stupidity for not taking a shot.

He was among the original Walter Reed whistle blowers who alerted the world to the black mold that was harming injured vets returning from Iraq and Afghanistan. His mission now is fighting vaccine hesitancy among troops and veterans.

ONE SHOT THE US MILITARY DOESN’T WANT TO TAKE

“I wish I could wrap my brain around this apprehension,” Eggleston, who is working with Blue Star Families and COVID Collaborative to address vaccine hesitancy among veterans and active duty troops. “If you see people die in other countries begging to have this [vaccine] so they can live another day or live another year, whatever the case is, you should be on board.”

Eggleston got both Pfizer shots and did not experience anything more than a sore arm each time, but his mother Rebecca, in her mid 70s, died less than two months ago waiting for hers. She was infected, he says, by an unvaccinated nurse at her retirement home in Virginia Beach.

Charles Eggleston poses with his mother, Rebecca. (Photo courtesy of Charles Eggleston)

Charles Eggleston is seen recovering from his injuries (Photo courtesy of Charles Eggleston)

“She was just waiting for them to give her the shot. And she contracted it from her nurse,” Eggleston explained.

“The nurse decided she wanted to go to a cousin’s birthday party. She basically infected half a dozen folks before they infected another dozen folks.”

The military is barred from ordering troops to get a vaccine that only has FDA emergency use authorization.

Today, Pfizer applied for full authorization which could change the military’s calculus about ordering hesitant troops to get vaccinated.

Secretary of Defense Lloyd Austin still says there are no plans to mandate members of the military get the Coronavirus vaccine, but encouraged more service members to roll up their sleeves and get the vaccine like he did.

US PULLOUT FROM AFGHANISTAN COULD LEAVE 17,000 INTERPRETERS’ LIVES IN DANGER

“I think armed with the right information, accurate information, troops will make or make good choices,” Austin told reporters, adding that the military is currently using 80 percent of the vaccines they have been given.

The White House says it will leave the decision about mandating vaccines to Austin.

“As it relates to the military, we would rely on the advice and guidance of the Secretary of Defense,” said White House press secretary Jen Psaki.

At Thursday’s press conference, Austin made clear what the Pentagon views as the greatest threat right now.

“Our top priority is to defend this nation and to protect our interests. And today, the most urgent challenge that we face is COVID-19,” Austin told reporters.

The Pentagon, however, has been hesitant to release exact numbers on vaccination rates. In February, officials said more than a third of the military offered the shot refused to get it.

Blue Star Families, a military advocacy group, did the original survey that alarmed the Pentagon about concerns over COVID vaccines last December and has another survey coming out soon.

CLICK HERE TO GET THE FOX NEWS APP

“The majority of military family members and service members were reluctant to get the vaccine, and even larger number, didn’t feel comfortable with the idea of giving it to their children,” said Kathy Roth-Douquet, CEO of Blue Star Families.

Today, Pfizer submitted a request today to the FDA for full approval. If it gets it, the Pentagon may change its mind about ordering troops to get the vaccine – to protect themselves and their units, and also their families.

AstraZeneca weighs seeking full U.S. approval for COVID shot, skipping emergency-use application

AstraZeneca PLC could skip asking the Food and Drug Administration for emergency-use authorization for its Covid-19 vaccine, according to people familiar with the matter—and instead pursue the more time-intensive application for a full-fledged license to sell the shot.

Such a move would further delay any rollout of AstraZeneca shots in the U.S., where the vaccine has already been made and stockpiled. But U.S. government and public-health officials have said they probably don’t need AstraZeneca shots because of ample supplies of three other shots already authorized for use.

The British drugmaker said last week it intended to apply for the emergency go-ahead within weeks. But it has also been considering a different path to getting the drug approved in the U.S., according to these people. That would involve taking what could be several more months to compile and review data necessary for what is known as a biologics license, essentially a more comprehensive, nonemergency seal of approval from the FDA.

WHAT WE KNOW ABOUT ASTRAZENECA VACCINE BLOOD CLOT REPORTS

The full license is the path most new medicines take on their way to the U.S. market. But Covid-19 vaccine makers including Pfizer Inc., Moderna Inc. and Johnson & Johnson have all sought and received emergency-use authorization as a stopgap, encouraged by the government, with plans eventually to apply for full-blown approval for their respective shots. The emergency-use application allowed all three to win quicker FDA approval in the pandemic.

AstraZeneca has long said it would go down that same route, but delays stretched out as it has struggled to pull together the large amount of data from tens of millions of doses of the vaccine already administered in the U.K.

“AstraZeneca continues to progress its FDA submission,” a company spokesman said Friday. “It is important to note the substantial size of the file—in addition to the U.S. trial data, the filing will also include analyses and pharmacovigilance from all studies to date, in addition to real-world evidence data.”

The shot has been accepted for emergency use in the U.K., across Europe and in more than a hundred other countries around the world. The FDA is requiring AstraZeneca to provide that data from real-world use, in addition to data from human clinical trials. Other shots weren’t yet being used widely when they went before the FDA.

The AstraZeneca shot has also been linked in Europe and elsewhere to very rare, but sometimes-fatal, serious blood clotting, an issue that European regulators, AstraZeneca and outside researchers are still studying.

U.S. officials got into a rare, public spat in March over the precise efficacy of the shot in large-scale human trials in the U.S., an episode health experts expected to complicate any review.

In ongoing talks between AstraZeneca and the U.S. government, the prospect of skipping the quicker, narrower emergency authorization and instead going for the fuller license has gained favor inside AstraZeneca, some of the people said. The U.S. government, which helped fund AstraZeneca’s vaccine U.S. testing and development, must sign off on any decision to skip an emergency-use application, according to a person close to the process and language in AstraZeneca’s U.S. government contract. A senior company executive said last week AstraZeneca could skip the emergency-use filing if government officials told the company to apply for full approval instead.

HOW DOES JOHNSON & JOHNSON’S COVID-19 VACCINE COMPARE TO MODERNA, PFIZER?

Given the scale of the data required for an emergency-use application, submitting a full application would probably add a month or two to the overall timeline, people close to the process said. It would avoid AstraZeneca’s needing to compile two separate sets of data for two different applications.

The U.S. has ordered so many doses of already-approved shots that there is little urgency in rolling out the AstraZeneca vaccine domestically. That is a big factor in the company’s discussions with U.S. government and FDA officials, the people familiar with the discussions say.

The AstraZeneca shot, developed in partnership with the University of Oxford, is a pillar of vaccination drives around the world, including in poorer countries lacking other options and in crisis-ridden India. It is cheaper and easier to transport than most other vaccines.

CLICK HERE TO GET THE FOX NEWS APP

Public-health experts and AstraZeneca executives see an FDA endorsement as a potential confidence boost for the vaccine, which has faced confusion over dosing and efficacy, delivery shortages and concerns about the rare blood-clotting issues.

AstraZeneca since December has supplied more than 300 million doses globally at no profit. The drugmaker lost around $40 million on the vaccine the first three months of this year, based on its reported 3-cent hit to per-share earnings for the quarter.

Early last year, the U.S. government bet big on the shot, pledging up to $1.2 billion to help develop the shot and secure 300 million shots.

WHO greenlights China’s Sinopharm COVID-19 vaccine

The World Health Organization on Friday announced it granted emergency use listing to Beijing’s COVID-19 vaccine, Sinopharm, marking the sixth vaccine in the world health agency’s arsenal.

Dr. Tedros Adhanom Ghebreyesus, WHO director-general, said the Strategic Advisory Group of Experts (SAGE) recommended the jab for use in all adults aged 18 and older on a two-dose regimen. The vaccine will be added to the agency’s co-led COVAX initiative in an effort to provide vaccines to low- and moderate-income countries worldwide.

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

“Vaccines remain a vital tool but right now the volume and distribution of vaccines is insufficient to end the pandemic,” Tedros said during a briefing.

Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine’s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.

Sinopharm hasn’t published its late-stage test results in scientific journals, so the WHO requested a breakdown of its data, which come mostly from the United Arab Emirates. A summary posted online by WHO suggests the vaccine is about 78% effective, with the caveat that all but a few hundred of the study volunteers were younger than 60.

The Associated Press contributed to this report.

CDC’s Nancy Messonnier, who warned coronavirus would cause ‘severe’ disruption, resigns

Dr. Nancy Messonnier, the Centers for Disease Control and Prevention (CDC) official who first warned last February “disruption to everyday life may be severe” as a result of coronavirus spread, is resigning. Messonnier reportedly sent an email to staff indicating that her last day would be May 14 and that she was taking on a new role with the nonprofit Skoll Foundation.

When asked during Friday’s White House COVID-19 briefing to elaborate further on Messonnier’s decision, agency director Dr. Rochelle Walensky heaped praise on her career and achievements and wished her well, but declined to comment.

“My family and I have determined that now is the best time for me to transition to a new phase of my career,” Messonnier reportedly penned to colleagues, according to the New York Times.

FLASHBACK: CORONAVIRUS DISRUPTION TO ‘EVERYDAY’ LIFE IN US ‘MAY BE SEVERE,’ CDC OFFICIAL WARNS

Messonnier had been the agency’s director of the National Center for Immunization and Diseases and was participating in regular briefings regarding the coronavirus when the illness first emerged. In the now-infamous Feb. 25, 2020 briefing, Messonnier had said that Americans should begin preparing for a potential outbreak while other officials continued relaying that the immediate threat to the public remained low.

“As more and more countries experience community spread, successful containment at our borders becomes harder and harder,” she had said during the briefing. “Ultimately we expect we will see community spread in this country. It’s not so much a question of if this will happen anymore, but rather more a question of when this will happen, and how many people in this country will have severe illness.”

She had warned that the virus moves “quite rapidly,” although at the time the World Health Organization (WHO) was still more than a week away from declaring the outbreak a pandemic.

“I understand this whole situation may seem overwhelming and that disruption to everyday life may be severe, but these are things people need to start thinking about now,” she had said.

President Trump was reportedly unhappy with how the message impacted the stock market, and allegations emerged that she was removed from public-facing briefings.

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

The New York Times reports that her resignation could signal the first in a series of changes coming at the agency under Walensky.

Health

Footer

Public File Info